Expression of inducible factors reprograms CAR-T cells for enhanced function and safety

Area of Science:

• Immunology
• Biotechnology
• Oncology

Background:

• Chimeric antigen receptor T (CAR-T) cell therapy shows promise in cancer immunotherapy but faces challenges in efficacy and safety.
• Current methods for enhancing CAR-T cells often involve constitutive transgene expression or multiple viral vectors, leading to uncontrolled responses and product variability.

Purpose of the Study:

• To develop a novel genetic platform, Uni-Vect, for enhanced CAR-T cell immunotherapy.
• To enable autonomous, antigen-induced production of accessory molecules in CAR-T cells using a single lentiviral vector.

Main Methods:

• Development of a single lentiviral vector (Uni-Vect) for constitutive CAR expression and autonomous accessory molecule production.
• In vivo validation of Uni-Vect's ability to express immunostimulatory cytokines, ameliorating antibodies, and transcription factors dependent on antigen activation.

Main Results:

• Uni-Vect demonstrated activation-dependent expression of beneficial molecules in vivo, including cytokines for improved efficacy and antibodies to mitigate cytokine-release syndrome.
• The platform successfully modulated T cell biology through transcription factor expression.
• Uni-Vect was also utilized as a tool for characterizing immune receptors.

Conclusions:

• Uni-Vect provides a robust platform for next-generation cellular immunotherapies, offering greater control over T cell responses.
• This system enhances the clinical applicability of CAR-T cell therapy by improving safety and efficacy profiles.